Alaunos Therapeutics, Inc. filed an 8-K on January 8, 2026, announcing the immediate termination of its contract with Cantor Fitzgerald & Co. as their financial advisor, effective on the same date. Additionally, the company has adopted new bylaws to improve stockholder proposals and nominations processes.